News

Novartis UK selected Macusoft for the Novartis BIOME UK HealthHub 21 Challenge, in collaboration with KQ Labs, the data-driven health accelerator of the Francis Crick Institute, and LifeArc, the charity helping to turn promising science into benefits for patients.

By combining world-leading scientific experience with the expertise of the data-driven health world, Novartis UK is supporting the development and uptake of technological solutions for digitising patient pathways and advancing remote care in a COVID-19 era.

Macusoft is working with DigitalHealth.London Accelerator in a programme aiming to speed up the development and scaling of digital innovations across health and care, and pioneer their adoption by the NHS. The programme will support Macusoft to develop and deploy solutions to eye disease management, one of the most pressing challenges facing the NHS.

The Accelerator is a partnership between London’s three AHSNs (Health Innovation Network, Imperial College Health Partners, UCLPartners), MedCity, CW+, and Guy’s and St Thomas’ Charity. It is supported by the Mayor of London; and is part-funded by the EU’s European Regional Development Fund.

SME of the Week blog

Macusoft has recently been awarded InnovateUK funding to develop artificial intelligence (AI) systems to automate the process of treatment recommendations for 3 of the most common diseases that affect the back of the eye and can cause rapid and devastating loss of vision and blindness.

KQ Labs is an intensive accelerator programme offered to high growth potential startup teams in the area of data-driven biomedical science.

Macular disease is the biggest cause of preventable sight loss in the developed world, and using genomics, clinical data, and digital imaging based AI systems, Macusoft prevents avoidable blindness.

Macusoft selected with five other technology companies for Imperial college’s inaugral Scaleable Business Award.

Imperial College and Central Working have awarded £250k to host the start-ups including Macusoft at the Translation & Innovation Hub (I-HUB) where they can work alongside Imperial researchers and turn scientific and technological innovations into new products and services.

The burden of chronic eye disease management and treatment is overwhelming health systems globally. Macusoft is changing that to prevent avoidable blindness worldwide.

Macusoft’s AI enables healthcare providers to improve the delivery of routine services cost-effectively through digital automation, enabling sight-saving treatment to available to all patients in advanced health economies as well as the developing world where 90% of the disease burden resides.

A global ageing demographic and diabetes epidemic is driving demand and improvements in eye service provision are required if we are to stop preventable blindness.

Macusoft AI to reduce sight-loss from diabetic related eye disease in India, the global epicenter of diabetes.

Diabetic Retinopathy is the leading cause of blindness of the working age population, however for 95% of patients it can be prevented. In India, 70% of the 1.3bn population resides in rural villages where eye-screening services are virtually non-existent, leading to unnecessary blindness.

Supporting the Vision Academy Eye Project, Macusoft is enabling eye-screening camps for diabetic patients in a region covering 7m people.